NASDAQ$ETON
Eton Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Eton Pharmaceuticals reported first quarter results with a significant increase in product sales and royalty revenue.
Eton Pharmaceuticals reported a strong first quarter, driven by record sales of ALKINDI SPRINKLE® and Carglumic Acid, which were boosted by an expanded sales force. The company also launched Betaine Anhydrous and acquired ET-600, a rare disease product candidate. Eton is approaching profitability with a solid cash position.
- Product sales and royalty revenue increased by 144% compared to Q1 2022 and 52% from Q4 2022, reaching $5.3 million.
- ALKINDI SPRINKLE® and Carglumic Acid achieved record sales, benefiting from the expanded sales force and targeted marketing initiatives.
- Betaine Anhydrous was launched, expected to synergize with Carglumic Acid due to shared prescriber base.
- Acquired ET-600, a product candidate for a rare pediatric endocrinology condition, with plans to file a New Drug Application in 2024.
Headline financials
Revenue & EPS history
Eton · Revenue · Quarterly
$5.3M
Revenue by segment
Eton · $5.3M total across 1 segment · Q1 2023
- Product Sales and Royalties$5.3M—100.0%
Forward guidance
Eton Pharmaceuticals anticipates continued growth, driven by ALKINDI SPRINKLE® and Carglumic Acid, as well as the newly launched Betaine Anhydrous.
Tailwinds
- Continued growth in ALKINDI SPRINKLE® and Carglumic Acid sales.
- Launch of Betaine Anhydrous expected to boost growth.
- Strong cash position to support portfolio expansion.
- Expectation to reach profitability in the near future.
- Potential for ET-600 to address a significant unmet need.
Headwinds
- Risks associated with drug development and commercialization.
- Uncertainties regarding regulatory filings and approvals.
- Dependence on successful development and commercialization of product candidates.
- Potential market competition and changing market conditions.
- Risks detailed in Eton's filings with the Securities and Exchange Commission.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+0.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+1.9%
Avg return
30 days after
48%
15 / 31 earnings
Positive
+36.0%
Q2 2023
Best reaction
-14.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | +6.7% | — | |
| Q4 2025 | +7.5% | +14.8% | +20.6% | |
| Q3 2025 | -11.4% | -8.8% | -15.0% | |
| Q2 2025 | +12.5% | +12.2% | +15.8% | |
| Q1 2025 | +0.4% | +14.6% | -16.2% | |
| Q4 2024 | -4.0% | -7.0% | -6.2% | |
| Q3 2024 | +9.2% | +3.2% | +25.2% | |
| Q2 2024 | +6.6% | +8.0% | +31.5% | |
| Q1 2024 | -7.8% | -2.4% | -3.0% | |
| Q4 2023 | -14.1% | -21.0% | -23.7% | |
| Q3 2023 | -13.7% | -16.6% | -19.1% | |
| Q2 2023 | +36.0% | +79.5% | +83.7% | |
| Q1 2023 | +2.8% | +2.6% | +10.3% | |
| Q4 2022 | +2.6% | +7.1% | -7.4% | |
| Q3 2022 | +18.5% | +20.9% | +22.8% | |
| Q2 2022 | -1.0% | -19.4% | -22.8% | |
| Q1 2022 | +1.3% | +6.5% | -4.9% | |
| Q4 2021 | +6.1% | +8.7% | -1.5% | |
| Q3 2021 | -3.4% | -9.2% | -20.7% | |
| Q2 2021 | -5.0% | -0.2% | +12.7% | |
| Q1 2021 | +5.2% | +7.5% | -13.4% | |
| Q4 2020 | -0.7% | -1.1% | +5.9% | |
| Q3 2020 | -1.5% | +2.9% | +19.9% | |
| Q2 2020 | -2.2% | +4.4% | +12.4% | |
| Q1 2020 | -9.2% | -10.3% | -1.1% | |
| Q4 2019 | -8.4% | -21.9% | -39.8% | |
| Q3 2019 | +1.9% | +2.3% | +9.2% | |
| Q2 2019 | +1.6% | -1.8% | -14.2% | |
| Q1 2019 | +3.2% | +12.2% | +5.9% | |
| Q4 2018 | -2.3% | +2.6% | -5.8% | |
| Q3 2018 | -8.1% | -4.8% | -3.2% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro